CalciMedica Inc (CALC)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.34-8.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CALC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
"The recent financing supports a pulmonary hypertension strategy, including a Phase 1b proof-of-concept trial using Auxora and the continued development of CM5480 as an oral therapy for chronic use,”…
Stated in 2 of 2 supplied quarters. Management reported: “"The recent financing supports a pulmonary hypertension strategy, including a Phase 1b proof-of-concept trial using Auxora and the continued development of CM5480 as an oral therapy for chronic use,” said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.” “• Auxora Phase 1b proof-of-concept trial in PAH planned: CalciMedica plans to evaluate Auxora in a Phase 1b trial in patients with pulmonary arterial hypertension to generate initial clinical evidence regarding the effects of CRAC channel inhibition on pulmonary vascular and right ventricular function.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“"The recent financing supports a pulmonary hypertension strategy, including a Phase 1b proof-of-concept trial using Auxora and the continued development of CM5480 as an oral therapy for chronic use,”…”
“Pulmonary Hypertension (PH) Program Update • Preclinical activities to advance CM5480 in PH underway: Studies are ongoing to further characterize the pharmacology, pharmacokinetics, and safety profil…”
Acute Pancreatitis (AP) Program Update • FDA alignment on Phase 2b trial design: On July 29, 2026, following a Type C Focused Meeting, CalciMedica announced that FDA aligned with the Company’s Phase…
Stated in 2 of 2 supplied quarters. Management reported: “Acute Pancreatitis (AP) Program Update • FDA alignment on Phase 2b trial design: On July 29, 2026, following a Type C Focused Meeting, CalciMedica announced that FDA aligned with the Company’s Phase 2b trial design for Auxora in AP.” “The primary endpoint will measure whether Auxora can reduce the development of new‑onset severe respiratory failure.”
“Acute Pancreatitis (AP) Program Update • FDA alignment on Phase 2b trial design: On July 29, 2026, following a Type C Focused Meeting, CalciMedica announced that FDA aligned with the Company’s Phase…”
“Recent Program Highlights: Acute Pancreatitis (AP) Program Update • Continued positive FDA engagement on pivotal program in AP: CalciMedica continues to engage constructively with the U.S. Food and D…”
The Company expects its cash and cash equivalents to fund its current operating plan into the second half of 2027.
Stated in 2 of 2 supplied quarters. Management reported: “The Company expects its cash and cash equivalents to fund its current operating plan into the second half of 2027.” “Gastroenterology . 2022;162(2):621-644. 2 Financial Results for the Second Quarter Ended June 30, 2026: Cash Position: Cash and cash equivalents were $18.6 million as of June 30, 2026.”
“The Company expects its cash and cash equivalents to fund its current operating plan into the second half of 2027.”
“The Company expects its cash position to be sufficient to fund its current operating plan into the fourth quarter of 2026.”
R&D Expenses: Research and development expenses were $2.1 million for the three months ended June 30, 2026, compared to $4.1 million for the three months ended June 30, 2025.
Stated in 2 of 2 supplied quarters. Management reported: “R&D Expenses: Research and development expenses were $2.1 million for the three months ended June 30, 2026, compared to $4.1 million for the three months ended June 30, 2025.” “The decrease of $2.7 million was primarily due to a decrease in preclinical and clinical trial related activities, consultants and personnel, and chemistry, manufacturing and controls activities.”
“R&D Expenses: Research and development expenses were $2.1 million for the three months ended June 30, 2026, compared to $4.1 million for the three months ended June 30, 2025.”
“R&D Expenses: Research and development expenses were $3.5 million for the three months ended March 31, 2026, compared to $4.2 million for the three months ended March 31, 2025.”
Advance Auxora in acute pancreatitis and pulmonary hypertension, including clinical-trial planning and FDA engagement.
Over the trailing year it converted 4.43x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
17 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-04.